New patent approved on the US market

AroCell announces today that the US Patent Office has approved and issued AroCell's patent US 11,959,919 B2, entitled "Predicting cancer progression".

The patent is one of AroCell's early patents that demonstrated the clinical significance of serum TK1 protein measurements using the specific antibodies against the C-terminal region of TK1 in cancer. This patent extends a previously approved European patent with the number EP 1,627,230 B1. The new patent is now valid until 2034.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com